Dionysus Digital Health Hopes To Be First To Market With Blood Test To Forecast Postpartum Depression

A digital health start-up aims to launch an at-home blood test and AI-driven app this fall that could predict risk of postpartum depression as early as in the third trimester. Still in its early stages, the company eventually intends to file for US FDA clearance of the test.

Baby Blues
• Source: Shutterstock

San Diego, CA-based start-up Dionysus Digital Health hopes to become the first company to receive US regulatory clearance for a blood test that can accurately predict a woman’s risk of postpartum depression.

Currently, there are no biological tests to identify a woman’s risk for postpartum depression, a condition that affects about 10%-15%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurology

More from Device Area

Somnee AI-Powered Sleep Wearable Raises $10M Seed Round

 

The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.

Aneira Health Launches New Precision Medicine Platform Exclusively For Women

 

Cecilia Lindgren, Aneira Health’s co-founder and chief science officer, said that the company has “redesigned the diagnostic model.” The subscription-based platform offers clinical-grade and AI diagnostics alongside clinical consultation.

Ultrahuman Launches Home Health Monitoring

 

Ultrahuman seeks to “create an environment that aligns with our bodies" by linking environmental parameters collected by Ultrahuman Home to health physiology, measured by the Ultrahuman Ring Air.